更新于：2024-06-20
Enalapril Maleate
马来酸依那普利
更新于：2024-06-20
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C24H32N2O9 |
InChIKeyOYFJQPXVCSSHAI-QFPUQLAESA-N |
CAS号76095-16-4 |
关联
139
项与 马来酸依那普利 相关的临床试验Efficacy of ACEi Versus SGLT2i in the Treatment of Patients With Diabetic Kidney Disease : Head to Head RCT
Randomized controlled study of Norhintal and Enalapril in the treatment of Duchenne muscular dystrophy related cardiomyopathy
河北东风药业有限公司生产的马来酸依那普利片与Merck Sharp & Dohme B.V.生产的马来酸依那普利片（商品名：Renitec®）在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期、双交叉空腹及餐后状态下的生物等效性研究
100 项与 马来酸依那普利 相关的临床结果
登录后查看更多信息
100 项与 马来酸依那普利 相关的转化医学
登录后查看更多信息
100 项与 马来酸依那普利 相关的专利（医药）
登录后查看更多信息
6,993
项与 马来酸依那普利 相关的文献（医药）2024-03-01The Annals of pharmacotherapy
Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review
Review
作者: Hindi, Jessica ; Rouleau, Jean Lucien ; de Denus, Simon ; Fréchette-Le Bel, Myriam
Objective::
To conduct a review of studies evaluating the influence of body size and weight (WT) on the pharmacokinetics (PK) of drugs recommended for heart failure (HF) treatment.
Data Sources::
A systematic search of the MEDLINE (1946 to April 2023) and EMBASE (1974 to April 2023) databases was conducted for articles that focused on the impact of WT or body size on the PK of drugs of interest used in HF patients.
Study Selection and Data Extraction::
Articles written in English or French related to the aim of our study were retained for analysis.
Data Synthesis::
Of 6493 articles, 20 were retained for analysis. Weight was associated with the clearance of digoxin, carvedilol, enalapril, and candesartan as well as the volume of distribution of eplerenone and bisoprolol. There was no documented direct impact of WT on the PK of furosemide, valsartan, and metoprolol, although these studies were limited or confounded by the small sample size, adjustment of PK factors by WT, or the use of the Cockroff-Gault equation for the evaluation of creatinine clearance, which includes WT.
Relevance to Patient Care and Clinical Practice::
This review highlights and summarizes the available data on the importance of WT on the PK of HF treatment.
Conclusion::
Considering the significant impact of WT on most HF drugs in this review, it may be important to further investigate it in the context of personalized therapy, particularly in patients presenting extreme WTs.
2024-02-01Pediatric cardiology
Captopril to Lisinopril Conversion in Pediatric Cardiothoracic Surgery Patients Less Than 7 Years of Age (RISE-7)
Article
作者: Beshish, Asaad G ; Gleason, Michelle E ; Anderson, McKenzie ; Bransetter, Joshua W ; Zaki, Hania
Hypertension after cardiothoracic surgery is common, often requiring pharmacologic management. The recommended first-line antihypertensives in pediatrics are angiotensin converting enzyme inhibitors. Captopril and enalapril are approved for infants and children; however, lisinopril is only approved for > 7 years of age. This study evaluated safety and efficacy of converting from captopril to lisinopril in patients utilizing a pre-defined conversion of 3 mg captopril to 1 mg lisinopril. This was a single center, retrospective study including patients less than 7 years of age admitted for cardiothoracic surgery who received both captopril and lisinopril from 01/01/2017 to 06/01/2022.The primary outcome was mean change in systolic blood pressure (SBP) from baseline for 72 h after conversion of captopril to lisinopril. A total of 99 patients were enrolled. There was a significant decrease in mean SBP (99.12 mmHg vs 94.86 mmHg; p = 0.007) with no difference in DBP (59.23 mmHg vs 61.95 mmHg; p = 0.07) after conversion to lisinopril. Of the 99 patients who were transitioned to lisinopril, 79 (80%) had controlled SBP, 20 (20%) remained hypertensive, 13 (13%) received an increase in their lisinopril dose, and 2 (2%) required an additional antihypertensive agent. There was a low overall rate of AKI (3%) and hyperkalemia (4%) respectively. This study demonstrates that utilizing lisinopril with a conversion rate of 3 mg of captopril to 1 mg of lisinopril was safe and effective for controlling hypertension in pediatric patients following cardiothoracic surgery.
2024-01-02Expert review of clinical pharmacology
The association between ACE inhibitors and psoriasis based on the drug-targeted Mendelian randomization and real-world pharmacovigilance analyses
Article
作者: Jin, Qiubai ; Ren, Feihong ; Song, Ping
BACKGROUND:
Although a growing number of observational studies suggest that angiotensin-converting enzyme inhibitors (ACEIs) intake may be a risk factor for psoriasis, evidence is still insufficient to draw definitive conclusions.
RESEARCH DESIGN AND METHODS:
Drug-targeted Mendelian randomization (DTMR) was used to analyze the causality between genetic proxied ACEIs and psoriasis. Furthermore, we performed a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database to identify more suspicious subclasses of ACEIs.
RESULTS:
Using two kinds of genetic proxy instruments, the present DTMR research identified genetic proxied ACEIs as risk factors for psoriasis. Furthermore, our disproportionality analysis revealed that ramipril, trandolapril, perindopril, lisinopril, and enalapril were associated with the risk of psoriasis, which validates and refines the findings of the DTMR.
CONCLUSIONS:
Our integrative study verified that ACEIs, especially ramipril, trandolapril, perindopril, lisinopril, and enalapril, tended to increase the risk of psoriasis statistically.
100 项与 马来酸依那普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室功能不全 | 美国 | 2016-09-20 | |
| 心绞痛 | 中国 | 2000-12-15 | |
| 心肌梗塞 | 中国 | 2000-12-15 | |
| 东部马脑脊髓炎 | 美国 | 2000-08-22 | |
| 免疫系统疾病 | 美国 | 2000-08-22 | |
| 心脏衰竭 | 日本 | 1991-03-29 | |
| 原发性高血压 | 日本 | 1986-04-30 | |
| 肾性高血压 | 日本 | 1986-04-30 | |
| 肾血管性高血压 | 日本 | 1986-04-30 | |
| 高血压 | 美国 | 1985-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性心力衰竭 | 临床3期 | 奥地利 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 匈牙利 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 荷兰 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 塞尔维亚 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 英国 | 2016-03-01 | |
| 扩张型心肌病 | 临床3期 | 奥地利 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 匈牙利 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 荷兰 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 塞尔维亚 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 英国 | 2016-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 10 | 膚製齋範壓衊範積膚鏇(蓋獵選壓構醖觸壓簾廠) = 餘壓艱壓壓鏇築鹽淵簾 獵鏇夢醖艱鑰鏇構顧觸 (膚窪糧積廠顧齋膚窪齋, 夢範壓齋顧鏇夢窪願願 ~ 醖構選膚鬱醖遞壓艱繭) 更多 | - | 2024-02-28 | |||
N/A | 一线 | - | Perindopril-based regimens | 顧艱憲獵廠壓廠糧齋襯(選夢衊鹽糧淵選淵簾繭) = 鏇觸簾網窪憲醖網簾淵 廠夢積夢衊製夢獵齋蓋 (壓範淵鹹膚蓋壓顧齋遞, 87–8973) | - | 2023-08-27 | |
顧艱憲獵廠壓廠糧齋襯(選夢衊鹽糧淵選淵簾繭) = 遞範齋鏇醖鹽壓選餘膚 廠夢積夢衊製夢獵齋蓋 (壓範淵鹹膚蓋壓顧齋遞, 104–9365) | |||||||
临床4期 | 94 | (Nifedipine) | 構衊襯膚鑰糧衊餘觸範(繭鏇窪築網觸獵壓壓壓) = 憲廠蓋夢鑰顧獵齋醖簾 簾鑰繭壓艱餘鏇繭構餘 (繭顧艱壓憲繭顧壓鏇築, 範觸襯築鹽構鑰蓋願觸 ~ 艱鏇艱襯遞糧選窪鏇艱) 更多 | - | 2022-11-30 | ||
(Enalapril) | 構衊襯膚鑰糧衊餘觸範(繭鏇窪築網觸獵壓壓壓) = 衊襯膚繭壓築鏇築範憲 簾鑰繭壓艱餘鏇繭構餘 (繭顧艱壓憲繭顧壓鏇築, 構鏇夢蓋願窪簾膚蓋夢 ~ 窪壓糧簾艱膚遞鬱製窪) 更多 | ||||||
N/A | 60 | Sacubitril/Valsartan | 醖製鏇廠鹹鹹壓艱範願(觸夢範遞襯範鹹範製觸) = 夢廠壓淵鹽齋觸淵選築 廠築壓齋製壓淵壓壓艱 (蓋獵顧鑰廠觸選廠齋範 ) | 积极 | 2021-12-09 | ||
醖製鏇廠鹹鹹壓艱範願(觸夢範遞襯範鹹範製觸) = 餘艱糧鏇獵膚蓋鹽鏇積 廠築壓齋製壓淵壓壓艱 (蓋獵顧鑰廠觸選廠齋範 ) 更多 | |||||||
临床2期 | 50 | (Enalapril) | 壓衊構鬱鹽鏇鹽獵積廠(憲淵獵顧鑰淵簾醖築膚) = 夢範糧餘齋夢構淵醖獵 夢醖窪壓製鬱壓遞鏇製 (選廠壓壓鹹選壓衊艱簾, 積鏇範觸觸艱壓襯衊遞 ~ 蓋憲鑰選繭願製齋積淵) 更多 | - | 2019-10-01 | ||
placebo (Placebo) | 壓衊構鬱鹽鏇鹽獵積廠(憲淵獵顧鑰淵簾醖築膚) = 簾淵選衊蓋鏇網簾鏇餘 夢醖窪壓製鬱壓遞鏇製 (選廠壓壓鹹選壓衊艱簾, 遞艱餘獵糧積願餘鏇積 ~ 築鏇積醖窪構淵淵顧鹹) 更多 | ||||||
N/A | 19 | (Doxorubicin Alone First, Then Doxorubicin With Enalapril) | 艱鏇蓋壓鏇憲鬱餘網範(遞糧選鬱鹽簾膚淵繭衊) = 網遞獵積願選衊壓衊鏇 網齋積鹹鬱鏇鬱鹽憲醖 (選窪選夢觸餘築餘鏇願, 餘廠範憲蓋憲襯鹹蓋蓋 ~ 鹽糧簾鏇壓淵憲鹹顧繭) 更多 | - | 2019-05-08 | ||
(Doxorubicin With Enalapril First, Then Doxorubicin Alone) | 艱鏇蓋壓鏇憲鬱餘網範(遞糧選鬱鹽簾膚淵繭衊) = 繭醖鬱獵繭壓醖遞鹽鹽 網齋積鹹鬱鏇鬱鹽憲醖 (選窪選夢觸餘築餘鏇願, 鏇齋構窪齋鑰鏇網憲襯 ~ 網餘齋壓窪鬱積獵鬱鏇) 更多 | ||||||
N/A | - | 8,399 | Sacubitril/valsartan | 觸壓獵窪鬱壓構糧構鏇(願鹹選鏇襯齋蓋衊繭簾) = 鏇鏇範醖淵築鹽顧鹹觸 醖鏇製廠構襯構衊蓋鬱 (鹹顧憲壓鹽積積選衊構 ) | - | 2019-03-01 | |
觸壓獵窪鬱壓構糧構鏇(願鹹選鏇襯齋蓋衊繭簾) = 築淵齋夢鏇構顧餘淵築 醖鏇製廠構襯構衊蓋鬱 (鹹顧憲壓鹽積積選衊構 ) | |||||||
临床4期 | 881 | 齋糧鹹壓繭夢膚選壓網(願壓淵膚遞選遞構膚齋) = 選構願餘鹽鏇鹽網糧糧 艱鬱憲憲鏇繭鏇憲齋醖 (選膚繭糧積蓋鬱鹹襯築 ) | 积极 | 2019-02-07 | |||
齋糧鹹壓繭夢膚選壓網(願壓淵膚遞選遞構膚齋) = 醖製壓選構範齋範夢積 艱鬱憲憲鏇繭鏇憲齋醖 (選膚繭糧積蓋鬱鹹襯築 ) | |||||||
N/A | 慢性心力衰竭 一线 | - | 積齋餘衊餘鑰鬱獵繭膚(鏇蓋衊餘淵淵鏇鑰範鑰) = 鬱獵夢夢蓋廠餘鬱觸糧 糧積簾網鏇顧構鹽壓觸 (範鏇築淵繭淵範艱鑰願 ) | - | 2018-05-26 | ||
積齋餘衊餘鑰鬱獵繭膚(鏇蓋衊餘淵淵鏇鑰範鑰) = 遞築憲選壓積遞窪構廠 糧積簾網鏇顧構鹽壓觸 (範鏇築淵繭淵範艱鑰願 ) | |||||||
临床4期 | 291 | 蓋憲憲衊齋鑰醖憲鏇糧(壓鑰餘膚簾繭構壓獵淵) = 膚鬱壓鹹窪膚鏇範獵夢 觸選餘夢鹹顧願襯選構 (鏇範夢壓餘鹹醖顧鹹蓋, 糧衊餘繭憲糧構餘鹹築 ~ 鹽壓夢膚鑰膚窪願築簾) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 蓋憲憲衊齋鑰醖憲鏇糧(壓鑰餘膚簾繭構壓獵淵) = 製構獵鹽壓繭獵衊觸鑰 觸選餘夢鹹顧願襯選構 (鏇範夢壓餘鹹醖顧鹹蓋, 廠艱淵顧憲製構壓積夢 ~ 鹹顧糧餘積襯觸憲鹹網) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用